Recent News

• 02.12.2026 - NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection
• 01.27.2026 - NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
• 01.12.2026 - NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue
• 01.05.2026 - NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
• 12.30.2025 - NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors
• 12.15.2025 - NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation
• 12.10.2025 - NeoGenomics to Present New ctDNA Research at SABCS 2025
• 12.08.2025 - NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025

Recent Filings

• 01.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.20.2026 - 144 Report of proposed sale of securities
• 01.15.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.15.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.12.2026 - EX-99.1 EX-99.1
• 01.12.2026 - 8-K Current report
• 01.05.2026 - 3 Initial statement of beneficial ownership of securities
• 01.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 12.30.2025 - EX-99.1 EX-99.1
• 12.30.2025 - 8-K Current report